PTJ
ARLZ

Paul Tudor Jones’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Paul Tudor Jones’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-19,500
Closed -$69K – 2146
2016
Q1 		$69K Buy
+19,500
New +$101K ﹤0.01% 1638

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $4.03B AUM 35.05% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Paul Tudor Jones's ARLZ Position: Q2 2016 in Review

Paul Tudor Jones sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2016, closing a stake of 19,500 shares — an estimated $69K sold.

Paul Tudor Jones first reported a position in ARLZ in Q1 2016 and held it in 1 quarter. The position peaked at $69K in Q1 2016. 95 funds tracked by Wall St. Rank hold ARLZ as of Q2 2016.

  • Paul Tudor Jones reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • Paul Tudor Jones sold 19,500 Aralez Pharmaceuticals Inc. shares in Q2 2016, an estimated $69K.
  • Paul Tudor Jones first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 1 quarter.
  • Paul Tudor Jones's Aralez Pharmaceuticals Inc. position peaked at $69K in Q1 2016.
  • 95 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2016.

Based on Tudor Investment Corp's 13F filing for Q2 2016, filed 15 Aug 2016.